Saravi, B.; Li, Z.; Basoli, V.; Grad, S.; Häckel, S.; Albers, C.E.; Alini, M.; Schmal, H.; Obid, P.; Lang, G. In Vitro Characterization of a Tissue Renin-Angiotensin System in Human Nucleus Pulposus Cells. Cells2022, 11, 3418.
Saravi, B.; Li, Z.; Basoli, V.; Grad, S.; Häckel, S.; Albers, C.E.; Alini, M.; Schmal, H.; Obid, P.; Lang, G. In Vitro Characterization of a Tissue Renin-Angiotensin System in Human Nucleus Pulposus Cells. Cells 2022, 11, 3418.
Saravi, B.; Li, Z.; Basoli, V.; Grad, S.; Häckel, S.; Albers, C.E.; Alini, M.; Schmal, H.; Obid, P.; Lang, G. In Vitro Characterization of a Tissue Renin-Angiotensin System in Human Nucleus Pulposus Cells. Cells2022, 11, 3418.
Saravi, B.; Li, Z.; Basoli, V.; Grad, S.; Häckel, S.; Albers, C.E.; Alini, M.; Schmal, H.; Obid, P.; Lang, G. In Vitro Characterization of a Tissue Renin-Angiotensin System in Human Nucleus Pulposus Cells. Cells 2022, 11, 3418.
Abstract
Low back pain is a clinically highly relevant musculoskeletal burden and is associated with inflammatory as well as degenerative processes of the intervertebral disc. However, the pathophysiology and cellular pathways contributing to this devastating condition are still poorly understood. Based on previous evidence, we hypothesize that tissue renin-angiotensin system (tRAS) components, including the SARS-CoV-2 entry receptor angiotensin-converting enzyme 2 (ACE2), are present in human nucleus pulposus (NP) cells and associated with inflammatory and degenerative processes. Experiments were performed with NP cells from 4 human donors. The existence of angiotensin II, angiotensin II type 1 receptor (AGTR1), AGTR2, MAS-receptor (MasR), and ACE2 in human NP cells was validated with immunofluorescent staining and gene expression analysis. Hereafter the cell viability was assessed after adding agonists and antagonists of the target receptors as well as angiotensin II in different concentrations for up to 48 hours of exposure. A TNF-α-induced inflammatory in vitro model was employed to assess the impact of angiotensin II addition and the stimulation or inhibition of the tRAS receptors on inflammation, tissue remodeling, expression of tRAS markers, and the release of nitric oxide (NO) into the medium. Further, protein levels of IL-6, IL-8, IL-10, and intracellular as well as secreted angiotensin II were assessed after exposing the cells to the substances, and inducible nitric oxide synthase (iNOS) levels were evaluated utilizing Western Blot. The existence of tRAS receptors and angiotensin II were validated in human NP cells. Cell viability analysis revealed no cytotoxic effects of angiotensin II. The AGTR1 inhibitor Candesartan and the MAS receptors AVE0991 showed cytotoxic effects at high concentrations (100 µM). The addition of angiotensin II only showed a mild impact on gene expression markers. However, there was a significant increase in NO secreted by the cells. The gene expression ratios of pro-inflammatory/anti-inflammatory cytokines IL-6/IL--10, IL-8/IL-10, and TNF-α /IL-10 were positively correlated with the AGTR1/AGTR2 and AGTR1/MAS1 ratios, respectively. The stimulation of the AGTR2 MAS-receptor and the inhibition of the AGTR1 receptor revealed beneficial effects on the gene expression of inflammatory and tissue remodeling markers. This finding was also present at the protein level. We did not find alterations in iNOS protein concentrations after adding the drugs. The current data showed that tRAS components are expressed in human NP cells and are associated with inflammatory and degenerative processes. Further characterization of the associated pathways is warranted. The findings indicate that tRAS modulation might be a novel therapeutic approach to intervertebral disc disease.
Medicine and Pharmacology, Orthopedics and Sports Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
